Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from PROCEPT BioRobotics ( (PRCT) ).
On June 10, 2025, PROCEPT BioRobotics held its annual stockholders meeting where all director nominees were elected to the board until 2028. Additionally, the selection of PricewaterhouseCoopers LLP as the independent accounting firm for 2025 was ratified, and the executive compensation package was approved.
The most recent analyst rating on (PRCT) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on PROCEPT BioRobotics stock, see the PRCT Stock Forecast page.
Spark’s Take on PRCT Stock
According to Spark, TipRanks’ AI Analyst, PRCT is a Neutral.
PROCEPT BioRobotics’ overall stock score reflects a mix of strengths and challenges. Strong revenue growth and strategic advancements provide a solid foundation, but ongoing financial losses and valuation concerns temper the outlook. Positive momentum from technical indicators and corporate events further support the score, although caution is advised due to potential overbought conditions.
To see Spark’s full report on PRCT stock, click here.
More about PROCEPT BioRobotics
PROCEPT BioRobotics Corporation operates in the medical technology industry, focusing on the development of innovative robotic solutions for minimally invasive surgical procedures.
Average Trading Volume: 995,405
Technical Sentiment Signal: Buy
Current Market Cap: $3.55B
Find detailed analytics on PRCT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue